The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? by Baker, Stuart G & Kramer, Barnett S
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
BMC Medical Research 
Methodology
Open Access BMC Medical Research Methodology  2002,  2 x Research article
The transitive fallacy for randomized trials: If A bests B and B bests 
C in separate trials, is A better than C?
Stuart G Baker*1 and Barnett S Kramer2
Address: 1Division of Cancer Prevention, National Cancer Institute and 2Offices of Disease Prevention and Medical Applications of Research, 
National Institutes of Health
E-mail: Stuart G Baker* - sb16i@nih.gov; B a r n e t tSK r a m e r-K r a merB@OD.NIH.GOV
*Corresponding author
Abstract
Background:  If intervention A bests B in one randomized trial, and B bests C in another
randomized trial, can one conclude that A is better than C? The problem was motivated by the
planning of a randomized trial, where A is spiral-CT screening, B is x-ray screening, and C is no
screening. On its surface, this would appear to be a straightforward application of the transitive
principle of logic.
Methods: We extended the graphical approach for omitted binary variables that was originally
developed to illustrate Simpson's paradox, applying it to hypothetical, but plausible scenarios
involving lung cancer screening, treatment for gastric cancer, and antibiotic therapy for clinical
pneumonia.
Results: Graphical illustrations of the three examples show different ways the transitive fallacy for
randomized trials can arise due to changes in an unobserved or unadjusted binary variable. In the
most dramatic scenario, B bests C in the first trial, A bests B in the second trial, but C bests A at
the time of the second trial.
Conclusion: Even with large sample sizes, combining results from a previous randomized trial of
B versus C with results from a new randomized trial of A versus B will not guarantee correct
inference about A versus C. A three-arm trial of A, B, and C would protect against this problem
and should be considered when the sequential trials are performed in the context of changing
secular trends in important omitted variables such as therapy in cancer screening trials.
Background
Consider three statements: A, B, and C. In formal logic, if
A implies B, and B implies C, then A implies C. This can
be illustrated by a Venn diagram in which set A lies entire-
ly within set B and set B lies entirely within set C. This im-
plies set A lies entirely within set C. This is an example of
transitivity. Extending this logical construct to the design
and interpretation of clinical trials, one might conclude
that (even with large sample sizes) if in a randomized tri-
al, intervention A is shown superior to intervention B, and
in another randomized trial intervention B is shown supe-
rior to C, then A will be shown superior to C in another
randomized trial.
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However, statistical association is not generally transitive.
Consider three random variables: A, B, C. If A is positively
correlated with B, and B is positively correlated with C,
then A may or may not be positively correlated with C [2].
To our knowledge no one has investigated transitivity of
results from separate randomized trials. In fact, for the
sake of perceived efficiency and limited resources, the
principle of transitivity is sometimes assumed in clinical
trial design. The possibility of a transitive fallacy surfaced
in discussions about a planned randomized clinical trial
to assess efficacy of low dose spiral computed tomography
(CT) for lung cancer screening.
The aim of the investigation is the use of graphical meth-
ods to explore conditions when transitive inference for
randomized trials does not hold. As the mathematician,
John Allen Paulos writes, "It's odd that logical acuity, rath-
er than helping one to clarify statements, often reveals
hidden ambiguities within them. Instead of leading one
to form more conclusions, it makes clear that fewer con-
clusions are justified."[3]
Methods
We extended the graphic in [1,4] for illustrating Simpson's
paradox. In the Simpson's paradox graphic, the horizontal
axis is the fraction of subjects with an unobserved variable
and the vertical axis is the probability of a binary out-
come. One diagonal line in the plot represents the effect
of unobserved variable on the probability of outcome,
given treatment A. A second diagonal line, which is lower
and parallel to the first, represents the effect of the unob-
served variable on the probability of outcome, given treat-
ment B. The graphic shows that if the fraction with the
unobserved variable differs between groups receiving A
and B (as in an observational study), then subjects receiv-
ing treatment B could have a higher probability of out-
come than subjects receiving A, even though the line for A
is higher than the line for B.
For this investigation, we added a third treatment to the
graphic and investigated three hypothetical, but plausible,
scenarios, one involving lung cancer screening, one in-
volving treatment for gastric cancer, and one involving an-
tibiotics. Unlike the Simpson's paradox example, in all the
scenarios there is an interaction between an unobserved
Figure 1
Screening for lung cancer. Hypothetical results are shown for A = spiral CT, B = x-ray, and C = no screening. In the sequential
study, results for B and C are similar in the first trial (when 30% of the subjects receive the new therapy), and results for A and
B are similar in the second trial (when 70% of the subjects receive the new therapy). However, as shown with three-arm trial,
it is incorrect to make the transitive inference that when 70% of the subjects receive the new therapy, the results for A and C
would be similar.
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binary variable and the intervention. For each scenario we
considered two study designs: (1) separate randomized
trials of B versus C and A versus B, and (2) a randomized
three-arm trial of A, B, and C. In the discussion below, we
emphasize that the trial sizes would be large enough to
eliminate considerations of simple statistical variation or
imprecision in measurement of outcome variables. We
also emphasize that the results would hold if there were
no bias from contamination or noncompliance.
Results
We present graphical illustrations of the transitive fallacy
in three hypothetical, but plausible, scenarios.
Lung cancer screening with improved therapy (Figure 1)
Let A denote spiral-CT screening, B denote chest x-ray
screening, and C denote the control group of no screening
or "usual care." The endpoint is lung cancer mortality rate.
A previous randomized trial of B versus C found similar
lung cancer mortality rates for the two interventions [5,6].
Currently there is discussion of a new randomized trial to
compare A and B. Suppose the new randomized trial
shows similar cancer mortality rates for A and B. Would
that constitute proof of similar cancer mortality rates for A
and C?
The unobserved binary variable is an indicator of whether
or not subjects received a (relatively) new (and effective)
therapy after early detection. Although type of therapy is
observable, it is not generally analyzed or reported in pa-
pers summarizing the results of screening trials. We sup-
pose that the new therapy decreases the lung cancer
mortality rates for A, B, and C, but at different rates (i.e. a
quantitative interaction). In addition, unless there is sub-
stantial overdiagnosis, it is reasonable that the greatest de-
crease would occur with A due to earliest detection. Also,
unless the therapy is effective at all stages of cancer, it is
reasonable that the smallest decrease would occur with C
due to late detection and greater total tumor burden.
We realistically assume that the percent of subjects who
receive the new therapy has increased over time as rand-
omized treatment trials establish its worth. For purposes
of illustration, we specify that in the first trial of B versus
C, 30 percent of the subjects receive the new therapy, and
in the planned second trial (either A versus B, or A versus
B versus C) 70 percent of the subjects will receive the new
therapy.
Figure 2
Treatment for gastric cancer. Hypothetical results are shown for A = radical gastrectomy / splenectomy, B = "simple" gastrec-
tomy, and C = radiation. In the sequential study, results for B and C differ in the first trial (when 30% of the subjects receive
effective supportive care), and results for A and B are similar in the second trial (when 70% of the subjects receive effective
supportive care). However, as shown with three-arm trial, it is incorrect to make the transitive inference that, when 70% of
the subjects receive effective supportive care, the results for A and C would differ.
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Figure 1 shows a realistic set of outcomes. In the first trial
the cancer mortality rate is similar for B and C. A second
trial of A versus B also indicates similar cancer mortality
rates (Figure 1, left). Under the transitive fallacy, one
would incorrectly conclude that the cancer mortality rates
for A and C are similar at the time of the second trial How-
ever, when 70% of the subjects receive the new therapy,
the three-arm trial correctly shows that A is substantially
better than C (Figure 1, right).
Cancer treatment with improved supportive care (Figure
2)
A second hypothetical example involves treatment for gas-
tric cancer. Let A denote, radical gastrectomy/splenecto-
my, B denote "simple" gastrectomy, and C denote
radiation. Suppose the endpoint is percent mortality over
some time period and the unobserved covariate is effec-
tive supportive care. It is plausible that supportive care im-
proves over time with better intensive care and better
antibiotics for any infections that arise.
In an earlier period when a small percentage of subjects re-
ceive effective supportive care, the more aggressive treat-
ments carry substantially more treatment-related
mortality. As shown in Figure 2 (left side), a randomized
trial of B versus C during this earlier period demonstrates
considerably higher mortality for B than C. In a later peri-
od, when a larger percentage of subjects receive effective
supportive care, the mortality rates converge. As shown in
Figure 2 (left side) a randomized trial of A versus B during
the later period indicates similar mortality rates. Under
the transitive fallacy, one would incorrectly conclude that
the cancer mortality rates for A and C differ substantially
at the time of the second trial. However, when a large per-
centage of subjects receive effective supportive care, the
three-arm trial correctly shows that mortality rates for A
and C are similar (Figure 2, right).
Antibiotic treatment with change in percent gram posi-
tive (Figure 3)
A third hypothetical example involves the use of empiric
antibiotics to treat clinical pneumonia. Suppose A is an
antibiotic that treats gram positive organisms but not
gram negative; B is an antibiotic that treats gram negative
but not gram positive pneumonias; and C is an antibiotic
that treats gram positive pneumonias better than A. The
endpoint is fraction successfully treated. Suppose the per-
cent of organisms that are gram positive is an unmeasured
Figure 3
Antibiotic treatment for clinical pneumonia. Hypothetical results are shown for A = antibiotic for gram-positive, B = antibiotic
for gram-negative, C = antibiotic for gram-positive that is more effective than A. In the sequential study, A bests B in the first
trial (when 80% of the subjects are gram positive), and B bests C in the second trial (when 10% of the subjects are gram posi-
tive). However, as shown with the three-arm trial, it would be incorrect to make the transitive inference that when 10% of the
subjects are gram-positive, A is better than C.
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covariate. This is a realistic scenario given that the spec-
trum of bacterial infections can shift over time, or can dif-
fer from hospital to hospital at the same time.
Suppose a randomized trial of A versus B has been com-
pleted and investigators are considering a randomized tri-
al of B versus C. (In this scenario, A versus B occurs prior
to B versus C, even though it is depicted farther to the right
on the graph.) We realistically assume the percent of or-
ganisms that are gram positive has decreased by the time
of the second trial. For purposes of illustration suppose 80
percent of the subjects are gram positive in the first trial
and only 10% are gram positive in the second trial.
In this situation A bests B in a randomized trial of patients
who mainly have gram-positive infections, and B bests C
in a randomized trial of patients with mainly gram-nega-
tive infections. (Figure 2 left). Under the transitive fallacy,
one would incorrectly conclude that when 10% of the
subjects have gram-negative infections, A would best C.
However, the three-arm study correctly shows that when
10% of the subjects have gram-negative infections, C
would best A (Figure 2 right).
Conclusion
Given only a previous randomized trial of B versus C and
a new randomized trial of A versus B, inference about A
versus C can be misleading. In contrast a three-arm rand-
omized trial of A, B, and C, will yield appropriate infer-
ence about both A versus B and A versus C. Validity of the
sequential studies strategy (B versus C, and A versus B)
rests on the assumption that there is no intervening im-
portant covariate that could confound the implied princi-
ple of transitivity. Given the amount of resources that are
often invested in large "definitive" clinical trials, the pos-
sibility of such covariates should be an explicit part of the
discussion in designing the trials and interpreting the re-
sults.
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